Background
Methods
Aim
Study population
Sample obtaining and serum determinations
Statistical analysis
Protein–protein/chemical interaction and pathway analysis networks
Results
Baseline and laboratorial characteristics in ACS vs ACS-AKI
ACS | ACS-AKI |
p
| |
---|---|---|---|
n (%) | 63 (80.7) | 15 (19.3) | |
Age | 58 (51–67) | 73 (63–78) | 0.001 |
Male (%) | 47 (74.6) | 11 (73.3) | 0.919 |
DM (%) | 27 (42.9) | 8 (53.3) | 0.463 |
HTN (%) | 35 (55.6) | 11 (73.3) | 0.136 |
SMK (%) | 41 (65.1) | 9 (60) | 0.712 |
NSTE-ACS(%) | 30 (47.6) | 10 (66.7) | 0.185 |
STEMI (%) | 33 (52.4) | 5 (33.3) | |
Death (%) | 2 (3.2) | 5 (33.3) | <0.001 |
BMI kg/m2
| 26.67 (24.22–29.4) | 26.56 (23.46–27.55) | 0.462 |
Heart rate | 75 (65–81) | 75 (64–86) | 0.849 |
SBP mmHg | 130.0 (116.0–150.0) | 120.0 (100.0–130.0) | 0.045 |
DBP mmHg | 80.0 (70.0–90.0) | 75.0 (70.0–80.0) | 0.206 |
Mean BP mmHg | 96.67 (85.67–110.0) | 90.67 (80.0–98.0) | 0.103 |
Hb g/L | 14.6 (13.7–15.3) | 14 (12.7–15.0) | 0.165 |
WBC ×109/L | 9.78 (7.88–12.2) | 12.8 (6.51–15.23) | 0.351 |
NT-ProBNP pg/mL | 1018.0 (217.7–2567.0) | 4746.0 (402.1–8519.0) | 0.034 |
TnI ng/mL | 9.92 (0.61–81.56) | 11.89 (0.19–37.06) | 0.596 |
hs-CRP mg/L | 9.75 (3.44–49.9) | 13.77 (5.67–169.79) | 0.29 |
Albumin mg/dL | 3.83 (3.6–4.02) | 3.82 (3.51–4.04) | 0.791 |
Na+ mmol/L | 140.0 (138.0–142.0) | 140.3 (136.7–144) | 0.817 |
K+ mmol/L | 4.07 (3.9–4.3) | 4.38 (3.93–4.94) | 0.101 |
BUN mg/dL | 16.36 (13.3–19.9) | 27.18 (21.18–38.0) | <0.001 |
HDL mg/dL | 35.8 (30.08–43.02) | 39.38 (30.58–49.7) | 0.303 |
LDL mg/dL | 96.63 (79.73–121.86) | 102.52 (67.36–111.55) | 0.368 |
T. Chol mg/dL | 160.36 (135.68–185.98) | 154.19 (122.75–171.27) | 0.274 |
TG mg/dL | 133.86 (102.72–197.1) | 105.7 (82.74–173.01) | 0.159 |
GRACE | 130 (96–152) | 156 (134–205) | 0.002 |
Admission Cr mg/dL | 0.958 (0.75–1.03) | 1.346 (1.02–1.8) | <0.001 |
Baseline Cr mg/dL | 0.803 (0.69–0.95) | 0.909 (0.682–1.084) | 0.482 |
ΔCr mg/dL | 0.057 (0.0–0.135) | 0.411 (0.331–0.8) | <0.001 |
Max Cr mg/dL | 0.97 (0.79–1.14) | 1.35 (1.03–1.9) | <0.001 |
ACS | ACS + AKI |
p
| |
---|---|---|---|
LTB4 pg/mL | 1630.04 (1114.72–1968.61) | 1711.674 (1092.63–1998.27) | 0.751 |
RvD1 ng/mL | 79.02 (78.38–79.87) | 79.68 (78.38–80.6) | 0.133 |
LxA4 pg/mL | 8.1 (5.91–9.0) | 7.23 (4.18–8.59) | 0.167 |
ET-1 pg/mL | 59.82 (40.27–80.36) | 70.58 (33.43–121.42) | 0.435 |
MMP-2 pg/mL | 2497.28 (2033.53–3100.16) | 2056.72 (1871.22–2705.97) | 0.068 |
MMP-9 pg/mL | 4615.7 (3103.64–5179.12) | 5375.66 (3737.82–6030.8) | 0.107 |
TIMP-1 pg/mL | 548.93 (420.28–749.69) | 544.25 (393.57–647.08) | 0.428 |
IL-1β pg/mL | 68.13 (0.55–242.91) | 400.1 (114.01–836.05) | 0.009 |
IL-6 pg/mL | 2399.67 (928.71–11,629.24) | 10,225.0 (1478.48–15,698.29) | 0.2 |
IL-8 pg/mL | 823.52 (513.57–1356.21) | 958.45 (620.41–2292.41) | 0.425 |
IL-10 pg/mL | 743.27 (206.63–1390.77) | 338.99 (197.90–24,162.37) | 0.929 |
Correlations with ΔCr
Generalized additive models in the worsening of renal function
Variable |
Effective df
|
F-value
| P for smoothed term |
---|---|---|---|
Agea
| 1.349 | 5.79 | 0.005 |
BMI | 4.778 | 17.79 | <0.001 |
Heart rate | 1 | 0.89 | 0.348 |
SBP | 3.129 | 8.52 | <0.001 |
DBP | 1 | 3.87 | 0.06 |
Mean BP | 4.43 | 11.95 | <0.001 |
Hb | 2.616 | 13.76 | <0.001 |
WBC | 4.05 | 16.95 | <0.001 |
Admission Cr | 3.096 | 420.36 | <0.001 |
NT-proBNP | 2.953 | 23.37 | <0.001 |
TnI | 3.092 | 13.35 | <0.001 |
CRP | 3.815 | 17.81 | <0.001 |
Alb | 1 | 1.22 | 0.274 |
Na | 5.501 | 51.95 | <0.001 |
K | 3.244 | 7 | <0.001 |
BUN | 6.031 | 48.61 | <0.001 |
GRACE | 2.496 | 37.57 | <0.001 |
LTB4 | 1 | 0.67 | 0.418 |
RvD1 | 2.218 | 6.8 | <0.001 |
LxA4 | 1.878 | 2.4 | 0.076 |
ET1 | 2.397 | 6.73 | <0.001 |
MMP2 | 1 | 0.1 | 0.754 |
MMP9 | 1 | 2.68 | 0.106 |
TIMP1 | 1 | 0 | 0.963 |
IL1b | 1 | 1.91 | 0.171 |
IL6 | 1 | 1.24 | 0.269 |
IL8 | 1 | 0.86 | 0.357 |
IL10 | 3.344 | 9.44 | <0.001 |